Indoco Remedies has received an update from the U.S. Food and Drug Administration (USFDA) regarding its Goa Plant-II & III facilities located in Verna Industrial Area, Goa, following an inspection conducted in July 2024.
The USFDA has classified the inspection status of the facility as ‘Official Action Indicated’ (OAI). This follows a previous inspection in February 2023, when the facility had also received an OAI status in May 2023.
Indoco Remedies Share Price history
| Day | Open | Close | Day’s change |
|---|---|---|---|
|
Fri, Oct 11 2024
|
₹341.80
|
₹337.30
|
-0.91%
|
|
Thu, Oct 10 2024
|
₹342.05
|
₹340.40
|
-0.42%
|
|
Wed, Oct 9 2024
|
₹338.35
|
₹341.85
|
|
|
Tue, Oct 8 2024
|
₹328.25
|
₹336.65
|
|
|
Mon, Oct 7 2024
|
₹335.05
|
₹329.65
|
-1.49%
|
|
Fri, Oct 4 2024
|
₹343.65
|
₹334.65
|
-1.44%
|
|
Thu, Oct 3 2024
|
₹348.00
|
₹339.55
|
-2.57%
|
|
Tue, Oct 1 2024
|
₹360.30
|
₹348.50
|
-2.80%
|
Indoco has been diligently working on a remedial action plan for the facility, expected to be completed by Q3 2024. The company had intended to notify the USFDA of its readiness for inspection post-remediation. However, the USFDA visited the facility in July 2024, while the remediation was still underway. As a result, the facility’s compliance status remains ‘OAI’ as of October 10, 2024.